New drug ESG406 enters human testing for Hard-to-Treat cancers

NCT ID NCT06979674

Recruiting now Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new drug called ESG406 in 556 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first find a safe dose, then expand to see if the drug can shrink tumors. The main focus is on safety and tolerability, with tumor response as a secondary goal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESG406 (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects are unknown. Results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED / METASTATIC SOLID TUMORS

Contacts and locations

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
The First Affiliated Hospital of Xi 'An Jiaotong University
RECRUITING

Xi’an, Shanxi, 710061, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.